Determination of psychoactivity and cerebral bioavailability of danitracene (WA 335) by quantitative pharmaco-EEG and psychometric investigations.
D000328:Adult; D000873:Anthracenes / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D001288:Attention / Q000187:drug effects; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography; D004644:Emotions / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology*; D011594:Psychometrics; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D011674:Pulse / Q000187:drug effects; D013997:Time Factors
D000873:Anthracenes; D010880:Piperidines; D011619:Psychotropic Drugs